LEXINGTON, Mass. and BOTHELL, Wash., Nov. 19, 2020 /PRNewswire/ -- FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM Sonosite, Inc. announced today the companies will virtually exhibit their portfolios of medical and enterprise imaging solutions at the 2020 Radiological Society of North America (RSNA) conference, held digitally from November 29 - December 5, 2020.
"Advancing healthcare requires collaboration between industry, clinicians, and IT professionals, especially when facing challenges that change the way in which we're able to connect," says Diku Mandavia, Senior Vice President and Chief Medical Officer, FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM Sonosite, Inc. "With a demonstrated legacy of quality imaging, and strengths in connectivity and interoperability, now more than ever we're excited to come together at RSNA to innovate for a healthier world."
At RSNA 2020, Fujifilm will exhibit solutions for:
Medical Imaging for a variety of modalities including:
Surgical Interoperability through Fujifilm's new systems integration solution, designed to enhance both clinical and IT workflows in the OR, endoscopic room, and interventional suite, bringing economic value to clinicians and administrative staff as well as hospital architects and equipment planners.
Fujifilm will also demonstrate how its AI-enabled platform REiLI® can be used for enterprise imaging, in the emergency room (ER), operating room (OR) and during general X-ray exams.
To view Fujifilm's suite of medical and enterprise imaging solutions, visit the company's RSNA landing page.
* Persona RF PREMIUM will be made available in the U.S. upon completion of regulatory requirements.
FUJIFILM Medical Systems U.S.A., Inc. is a leading provider of innovative diagnostic imaging products and medical informatics solutions that meet and exceed the evolving needs of healthcare facilities today and into the future. It's ever expanding medical imaging solutions span digital radiography (DR), detectors, portables and suites, mammography systems with digital breast tomosynthesis, computed tomography solutions for oncology and radiology applications, technologically advanced flexible and surgical endoscopy and fluoroscopy solutions. Fujifilm enables interoperability through its Systems Integration offering as well as its comprehensive, AI-supported Synapse® Enterprise Imaging portfolio, which includes the TeraMedica Division of Fujifilm. Fujifilm's in vitro diagnostics (IVD) portfolio includes clinical lab reagents, and biomarkers to assess the risk for the development of hepatocellular carcinoma in patients with chronic liver disease. FUJIFILM Medical Systems U.S.A., Inc. is headquartered in Lexington, Massachusetts. For more information please visit www.fujifilmhealthcare.com.
FUJIFILM Holdings Corporation, Tokyo, Japan, brings cutting edge solutions to a broad range of global industries by leveraging its depth of knowledge and fundamental technologies developed in its relentless pursuit of innovation. Its proprietary core technologies contribute to the various fields including healthcare, graphic systems, highly functional materials, optical devices, digital imaging and document products. These products and services are based on its extensive portfolio of chemical, mechanical, optical, electronic and imaging technologies. For the year ended March 31, 2020, the company had global revenues of $22.1 billion, at an exchange rate of 109 yen to the dollar. Fujifilm is committed to responsible environmental stewardship and good corporate citizenship. For more information, please visit: www.fujifilmholdings.com.
SOURCE FUJIFILM Medical Systems U.S.A., Inc. and FUJIFILM Sonosite, Inc.